Sofinnova Investments related stories
All articles and analysis
Biotech bang for buck(2)Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
- Biotech bang for buck
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
- QUALCOMM invests in Streamezzo
QUALCOMM Ventures has invested in French mobile software company Streamezzo, as venture capital firms attempt to find alternative ways of making profits from the mobile industry.
- Deal round-up 10/01/03
Benchmark backs BridgCo second round; AXA leads E10m mechanical systems round; Sofinnova invests in digital storage business; 3i backs Vanguard Healthcare round;Nordic Biotech leads Biotica funding
- Deal round up 05/11/02
DrKC increases Euromedic investment; Sofinnova invests in US biopharma round; ICC backs 2PM Technologies second round
- Index Ventures leads E34m financing round for Cellzome
The biopharmaceutical company will use the funding to boost infrastructure, programmes and recruit staff.
- Salveo Completes Additional Financings and Acquisition
Specialty pharmacy company Salveo Specialty Pharmacy has completed a second round of equity and debt funding and the subsequent acquisition of Mission Road Pharmacy. Salveo Specialty Pharmacy is backed by Three Arch Partners, NewSpring Capital and Petra Capital Partners. The additional equity financing was led by new investor Sofinnova Ventures. The debt financing included additional subordinated debt provided by Petra, as well as a new senior credit facility provided by Regions Bank.
The New Fundraising Kids on The BlockThe ratio of new to follow-on VC funds may have dropped this year, but the four firms profiled here have had little issues raising funds to date
- Mirna Therapeutics Closes $34.5M
Mirna Therapeutics Inc., a biopharmaceutical company developing therapeutics in cancer, has raised a $34.5 million Series C financing. Sofinnova Ventures led the round, with participation from investors including New Enterprise Associates, Pfizer Ventures, Osage University Partners, and Correlation Ventures.
- Aclaris Therapeutics Closes $21M Series A
Aclaris Therapeutics Inc., a specialty pharmaceutical company focused on dermatology, has raised $21 million. The Series A was led by Vivo Ventures and Fidelity Biosciences with participation from Sofinnova Ventures. The money will be used for product development.